P
Phanes Therapeutics
A company focused on innovative drug discovery and early development in immuno-oncology and eye disease
About Phanes Therapeutics
Phanes Therapeutics, Inc. operates as a clinical-stage biotechnology company with a sharp focus on oncology. Founded in July 2016 by Dr. Ming Wang, an industry veteran with extensive experience at global pharmaceutical giants like Johnson & Johnson, Amgen, and Pfizer, the company is headquartered in San Diego. Dr. Wang's background includes a Ph.D. in Biochemistry and an MBA, and he has a track record of leading drug discovery and development programs in metabolic diseases and oncology, which directly informs the company's strategic direction.
The company's business model centers on the discovery and development of novel biologic drugs to address significant unmet medical needs in cancer. Phanes Therapeutics generates value by advancing its proprietary pipeline through clinical trials, with a strategy that includes potential out-licensing, development collaborations, and strategic partnerships with larger pharmaceutical companies. This is evidenced by its clinical trial collaborations with major players like Merck, BeiGene, and Roche to evaluate its drug candidates in combination with established therapies.
Phanes has built its pipeline by leveraging three proprietary technology platforms for creating bispecific antibodies: PACbody®, for constructing stable, native IgG-like bispecific antibodies; SPECpair®, which allows for conventional, more efficient manufacturing processes; and ATACCbody®, designed to modulate antibody activity to minimize risks like cytokine release syndrome in solid tumor treatments. These platforms received registered trademarks from the U.S. Patent and Trademark Office in January 2024.
The company's clinical pipeline includes three main assets. PT199 (mavrostobart) is a monoclonal antibody targeting CD73 to counter the immunosuppressive tumor microenvironment and is being evaluated in the MORNINGSTAR Phase I/II study for advanced solid tumors. PT886 (spevatamig) is a first-in-class bispecific antibody targeting both Claudin 18.2 and CD47, developed to kill tumor cells via multiple immune pathways. It has received Orphan Drug and Fast Track designations from the FDA for pancreatic cancer and is being studied in the TWINPEAK trial. PT217 (peluntamig) is another first-in-class bispecific antibody targeting DLL3 and CD47 for cancers like small cell lung cancer (SCLC) and neuroendocrine tumors. It is also under evaluation in a Phase I/II trial known as SKYBRIDGE and has received both Orphan Drug and Fast Track designations.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- San Diego, United States
- Employees
- 29
- Open positions
- 1
- Dealroom signal
- 74.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| OtherOther financing | Jan 2024 | $0 | — | Undisclosed | ↗ |
| SERIES B✓Equity / VC | May 2021 | $40M | $160M | Delos Capital · HSG · Volcanics Venture · Dyee Capital | — |
Growth signals
Latest recorded traffic for Phanes Therapeutics is 3.2K monthly website visits, up 33.3% over the last three months. Phanes Therapeutics's team grew 16% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Phanes Therapeutics in the San Diego ecosystem
The Phanes Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Delos Capital
HSG
Volcanics Venture
Dyee Capital- WFWen Zhou Fund
Other known investors1 additional known investor
- KCKaitai Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Phanes Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Phanes Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







